Table 2.

Success rate of PDX for various type of cancers grafted on different sites and strains

Tumor type	Available model	Mice strain	Implantation site	Engraftment rate (%)	Reference
Colorectal cancer	130	NOD/SCID	s.c.	87	[18]
Colorectal cancer	54	Nude	s.c.	64	[19]
Colorectal cancer	41	Nude	Orthotopic	89	[20]
Breast cancer	25	Nude	s.c.	13	[21]
Breast cancer	12	NOD/SCID with estrogen supplementation for ER+ tumors	Mammary fat pad	27	[22]
NSCLC	25	NOD/SCID	s.c.	25	[23]
NSCLC	32	NOD/SCID	Renal capsule	90	[24]
Pancreatic ductal carcinoma	42	Nude	s.c.	61	[25]
Pancreatic ductal carcinoma	16	Nude	Orthotopic	62	[26]
SCCHN	22	NSG	s.c.	85	[27]
SCCHN/SCC	21	Nude	s.c.	54	[28]
Uveal melanoma	25	NOD/SCID	s.c.	28	[29]
Gastric cancer	15	Nude and NOG	s.c.	24	[30]
Ovarian cancer	29	NSG	i.p.	31	[31]
Prostate cancer	31	NOD/SCID	Subrenal capsule	95	[32]
Renal cell carcinoma	30	Nude	s.c.	8.9	[33]

PDX, patient-derived xenograft; NOD, nonobese diabetic; SCID, severely compromised immune deficient; s.c., subcutaneous; ER, estrogen receptor; NSCLC, non-small cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; NSG, NOD-SCID mice with IL-2Rγnull; SCC, squamous cell carcinoma; NOG, NOD-SCID mice with γc null; i.p., intraperitoneal.